ArticleiScience2025
An engineered VSV-vectored rabies vaccine with an RABV-G-L71S mutation.
Article in iScience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A Rabies Virus Glycoprotein Subunit Vaccine Produced inVaccines · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A replicating recombinant rabies vaccine, rVSV-RABV, was constructed using vesicular stomatitis virus (VSV) expressing the rabies virus glycoprotein (RABV-G, SAD-B19 strain). A leucine-to-serine mutation at position 71 (L71S) in the RABV-G extracellular domain significantly enhanced the viral titer and G protein expression. The derived strain, rVSV-RABV-L71S, demonstrated production and immunogenic advantages. As an inactivated vaccine formulated with GEL-02 adjuvant, it induced stronger neutralizing antibody responses, along with innate and Th1-biased T cell immunity in mice, compared to commercially inactivated vaccines. As a live vaccine, it conferred robust protection against the CVS-24 challenge in mice (NIH titer ∼4.8-fold higher than reference) and elicited superior neutralizing antibodies in dogs. Both inactivated and live rVSV-RABV-L71S formulations exhibited favorable safety profiles. rVSV-RABV-L71S represents a promising, low-cost, high-efficacy rabies vaccine candidate suitable for widespread use in developing countries.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.